Overview
In plain English
BPC-157 is a small peptide — fifteen amino acids long — originally identified in human gastric juice. It is one of the most widely studied compounds in the recovery category.
People use it for slow-healing soft-tissue problems: tendon and ligament strains, muscle tears, joint niggles that keep coming back, and gut irritation. The interest comes from animal studies where it improved blood supply to damaged tissue and sped up repair.
- What it isA 15-amino-acid peptide, injected subcutaneously
- Mainly used forTendon, ligament, muscle and gut recovery
- Typical protocol500mcg once daily for 4–8 weeks
How it works
What it actually does
Healing is limited by blood supply. Damaged tendon and ligament tissue has very little of it, which is why these injuries take months rather than weeks.
BPC-157's main reported effect is on that bottleneck. In animal studies it encourages the growth of new blood vessels into damaged tissue and helps repair cells move to where they are needed.
Almost all of the evidence is from animal and laboratory work. Human trials are limited. It is not a licensed medicine anywhere.
The science in detail
BPC-157 is a 15-residue fragment corresponding to a partial sequence of Body Protection Compound, a protein isolated from human gastric juice. It carries no cysteine residues and no disulphide constraint, and is notable within the peptide literature for resisting hydrolysis in gastric acid — the property from which the "stable gastric pentadecapeptide" designation derives.
No single high-affinity receptor for BPC-157 has been identified. The mechanistic literature instead describes convergence on two systems. The first is angiogenic signalling. Hsieh et al. (Journal of Molecular Medicine, 2017) reported that BPC-157's pro-angiogenic activity is associated with activation and upregulation of VEGFR2, with downstream signalling through the Akt–eNOS axis; VEGFR2 blockade attenuated the effect. This places the compound upstream of endothelial cell migration and tube formation rather than acting as a direct growth factor mimetic.
The second is the nitric oxide system. Work from Sikirić's group and others reports that BPC-157 modulates NO production bidirectionally, counteracting both L-NAME-induced NO blockade and L-arginine-induced NO excess in the same models. Hsieh et al. (Scientific Reports, 2020) described modulation of vasomotor tone via a Src–caveolin-1–eNOS pathway. The practical consequence in these models is homeostatic rather than unidirectional: the peptide appears to restore perturbed NO signalling in either direction.
In connective tissue specifically, Chang et al. (Journal of Applied Physiology, 2011) reported increased tendon fibroblast outgrowth, survival and migration in vitro, with associated changes in focal adhesion kinase and paxillin signalling — the machinery governing cell adhesion and directed migration during repair.
This distinguishes BPC-157 from TB-500, the adjacent recovery-research compound. TB-500 acts intracellularly on the actin cytoskeleton through G-actin sequestration. BPC-157's described actions are predominantly extracellular and vascular. The two are frequently studied together for that reason.
The entire evidence base is preclinical — rodent and in vitro. Human clinical trial data are limited, and reviews such as Józwiak et al. (Pharmaceuticals, 2025) are explicit about this gap.
Evidence
What the research shows
Improves blood supply to damaged tissue
In animal studies it triggered new blood vessel growth — the main thing that limits tendon and ligament healing.
Helps repair cells migrate
Laboratory work on tendon cells showed faster growth, better survival and improved movement toward the injury site.
Widely studied for gut irritation
A large share of the published work looks at protection of the stomach and intestinal lining.
Evidence is preclinical
The research is overwhelmingly animal and in-vitro. Controlled human trial data remain limited.
Mixing & dosage
How to mix and dose it
These are the mixing and dosage instructions supplied by Purist Peptides and the manufacturer for this product.
A 3ml vial of bacteriostatic water is included free with every peptide vial you order, so you have what you need to mix this on arrival.
BPC-157 10mg
Step 1 — mix your vial
- Draw up 2ml of bacteriostatic water into a syringe
- Wipe the rubber top of your vial with an alcohol swab and let it dry
- Insert the needle then slowly and carefully push the water down the inside wall of the vial — do not inject water straight onto the peptide powder
- Gently roll the vial between your palms until the powder dissolves completely
- Do not shake
- Allow to settle in the fridge for 5–10 minutes. The liquid should look clear
Step 2 — draw & inject your dose
Use a 1ml insulin syringe to draw and inject your dose. A 1ml syringe = 100 units.
With 2ml of water added, each 0.1ml (10 units) you draw = 500mcg of BPC-157.
| Stage | Dose | On the syringe |
|---|---|---|
| Starting | 250mcg daily | 5 units |
| Standard | 500mcg daily | 10 units |
Vial duration at standard dose: 20 days
When to inject: Once daily. For acute injury, twice daily — morning and evening.
Cycle length: 4 to 8 weeks, then reassess.
How to inject
- Wipe your injection site with an alcohol swab and let it dry
- Pinch a small fold of skin on your abdomen or inject near the area of concern
- Insert the needle at a 45-degree angle into the pinched skin
- Slowly push the plunger down until empty
- Pull the needle out and apply gentle pressure with the swab
- Dispose of the needle safely in a sharps container — never recap or reuse
Storage
Keep refrigerated at 2 to 6 degrees Celsius at all times after mixing. Do not freeze. Protect from light and label the vial with the date you reconstituted it. Discard any solution that is hazy, discoloured or contains particles.
For informational purposes only. This is not medical advice. Speak to a qualified healthcare professional before starting any compound.
Questions
Frequently asked questions
What is BPC-157 studied for?
Published preclinical work covers tendon, ligament and muscle injury models, gastrointestinal mucosal integrity, and nitric oxide signalling. Reviews including Józwiak et al. (Pharmaceuticals, 2025) survey this literature. The work is overwhelmingly rodent and in vitro; human clinical evidence is limited.
How does BPC-157 differ from TB-500?
BPC-157's described actions are largely extracellular and vascular, centring on VEGFR2 and nitric oxide signalling. TB-500 acts intracellularly, sequestering G-actin and influencing cytoskeletal remodelling and cell migration. Because the mechanisms are distinct rather than overlapping, the two are commonly examined in parallel.
Does BPC-157 bind a specific receptor?
No single high-affinity receptor has been identified. The mechanistic literature describes convergence on VEGFR2-associated angiogenic signalling and on modulation of the nitric oxide system, rather than a defined ligand-receptor pair. This remains an open question in the field.
Why is it described as "stable gastric"?
The designation reflects the peptide's reported resistance to hydrolysis in human gastric juice, a property unusual among peptides of this size and the basis of much of the early gastrointestinal research interest.
How is purity verified?
Every batch is assayed by independent HPLC at Bioindustrial Services in Boksburg. We do not rely on the manufacturer's own certificate alone. The assay report for the batch you receive is available on request, and our full testing protocol is set out at Quality Standards.
How long does delivery take?
Orders are dispatched from South Africa, with timelines varying by region and courier. Current dispatch and transit windows are set out at Delivery Process.
Can I return an order?
Because these are laboratory compounds, returns are not accepted once an order has shipped. If your parcel arrives damaged, contact us within 48 hours with photographs of the packaging and product and we will arrange a replacement. The full terms are set out in our Refund Policy.
Ready to order BPC-157?
Independently assayed to 99%+ purity. Research use only.
Add to cart — R 500.00The Purist Research Standard
Precision-engineered peptides designed to maintain structural integrity under rigorous laboratory conditions.
Optimized Logistics & Fulfillment
Our logistics and fulfillment protocols are engineered to prioritize research stability.
≥99% Research-Grade Purity
Every compound is synthesized to exceed a 99% purity threshold.
Third-Party Laboratory Verified
We maintain total transparency through independent COA.
Precision Lyophilization Technology
Our advanced flash-freeze and vacuum-drying process.
Controlled Synthesis Environment
Produced in sterile, ISO-compliant facilities.
Targeted Research Utility
Engineered as reliable biological models.
Recommended Products
Essential Compounds for Precision Research: Top-Tier Peptides Verified for Structural Integrity.
Testimonials
Real feedback from customers who prioritize purity, precision, and uncompromising quality standards.
